Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 102

1.

Endogenous angiogenesis inhibitors prevent adaptive capillary growth in left ventricular pressure overload hypertrophy.

Nikolova A, Ablasser K, Wyler von Ballmoos MC, Poutias D, Kaza E, McGowan FX, Moses MA, Del Nido PJ, Friehs I.

Ann Thorac Surg. 2012 Nov;94(5):1509-17. doi: 10.1016/j.athoracsur.2012.05.052. Epub 2012 Jul 12.

PMID:
22795062
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Vascular endothelial growth factor delays onset of failure in pressure-overload hypertrophy through matrix metalloproteinase activation and angiogenesis.

Friehs I, Margossian RE, Moran AM, Cao-Danh H, Moses MA, del Nido PJ.

Basic Res Cardiol. 2006 May;101(3):204-13. Epub 2005 Dec 23.

PMID:
16369727
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

TIMP-2 mutant decreases MMP-2 activity and augments pressure overload induced LV dysfunction and heart failure.

Givvimani S, Kundu S, Narayanan N, Armaghan F, Qipshidze N, Pushpakumar S, Vacek TP, Tyagi SC.

Arch Physiol Biochem. 2013 May;119(2):65-74. doi: 10.3109/13813455.2012.755548. Epub 2013 Feb 11.

PMID:
23398532
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Vascular endothelial growth factor prevents apoptosis and preserves contractile function in hypertrophied infant heart.

Friehs I, Barillas R, Vasilyev NV, Roy N, McGowan FX, del Nido PJ.

Circulation. 2006 Jul 4;114(1 Suppl):I290-5.

PMID:
16820588
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Estrogen improves TIMP-MMP balance and collagen distribution in volume-overloaded hearts of ovariectomized females.

Voloshenyuk TG, Gardner JD.

Am J Physiol Regul Integr Comp Physiol. 2010 Aug;299(2):R683-93. doi: 10.1152/ajpregu.00162.2010. Epub 2010 May 26.

PMID:
20504902
[PubMed - indexed for MEDLINE]
Free Article
6.

Mitochondrial division/mitophagy inhibitor (Mdivi) ameliorates pressure overload induced heart failure.

Givvimani S, Munjal C, Tyagi N, Sen U, Metreveli N, Tyagi SC.

PLoS One. 2012;7(3):e32388. doi: 10.1371/journal.pone.0032388. Epub 2012 Mar 27.

PMID:
22479323
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Matrix metalloprotease activity is enhanced in the compensated but not in the decompensated phase of pressure overload hypertrophy.

Tozzi R, Palladini G, Fallarini S, Nano R, Gatti C, Presotto C, Schiavone A, Micheletti R, Ferrari P, Fogari R, Perlini S.

Am J Hypertens. 2007 Jun;20(6):663-9.

PMID:
17531925
[PubMed - indexed for MEDLINE]
8.

Up-regulation of soluble vascular endothelial growth factor receptor-1 prevents angiogenesis in hypertrophied myocardium.

Kaza E, Ablasser K, Poutias D, Griffiths ER, Saad FA, Hofstaetter JG, del Nido PJ, Friehs I.

Cardiovasc Res. 2011 Feb 1;89(2):410-8. doi: 10.1093/cvr/cvq321. Epub 2010 Oct 8.

PMID:
20935166
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Lack of tissue inhibitor of metalloproteinases 2 leads to exacerbated left ventricular dysfunction and adverse extracellular matrix remodeling in response to biomechanical stress.

Kandalam V, Basu R, Moore L, Fan D, Wang X, Jaworski DM, Oudit GY, Kassiri Z.

Circulation. 2011 Nov 8;124(19):2094-105. doi: 10.1161/CIRCULATIONAHA.111.030338. Epub 2011 Oct 10.

PMID:
21986284
[PubMed - indexed for MEDLINE]
Free Article
10.

Targeted deletion of matrix metalloproteinase 2 ameliorates myocardial remodeling in mice with chronic pressure overload.

Matsusaka H, Ide T, Matsushima S, Ikeuchi M, Kubota T, Sunagawa K, Kinugawa S, Tsutsui H.

Hypertension. 2006 Apr;47(4):711-7. Epub 2006 Feb 27.

PMID:
16505197
[PubMed - indexed for MEDLINE]
Free Article
11.

Promoting angiogenesis protects severely hypertrophied hearts from ischemic injury.

Friehs I, Moran AM, Stamm C, Choi YH, Cowan DB, McGowan FX, del Nido PJ.

Ann Thorac Surg. 2004 Jun;77(6):2004-10; discussion 2011.

PMID:
15172254
[PubMed - indexed for MEDLINE]
12.

Excessive activation of matrix metalloproteinases coincides with left ventricular remodeling during transition from hypertrophy to heart failure in hypertensive rats.

Iwanaga Y, Aoyama T, Kihara Y, Onozawa Y, Yoneda T, Sasayama S.

J Am Coll Cardiol. 2002 Apr 17;39(8):1384-91.

PMID:
11955860
[PubMed - indexed for MEDLINE]
13.

Tumor escape from endogenous, extracellular matrix-associated angiogenesis inhibitors by up-regulation of multiple proangiogenic factors.

Fernando NT, Koch M, Rothrock C, Gollogly LK, D'Amore PA, Ryeom S, Yoon SS.

Clin Cancer Res. 2008 Mar 1;14(5):1529-39. doi: 10.1158/1078-0432.CCR-07-4126.

PMID:
18316578
[PubMed - indexed for MEDLINE]
Free Article
14.

MMP-2/TIMP-2/TIMP-4 versus MMP-9/TIMP-3 in transition from compensatory hypertrophy and angiogenesis to decompensatory heart failure.

Givvimani S, Tyagi N, Sen U, Mishra PK, Qipshidze N, Munjal C, Vacek JC, Abe OA, Tyagi SC.

Arch Physiol Biochem. 2010 May;116(2):63-72. doi: 10.3109/13813451003652997.

PMID:
20230216
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Inhibition of tumor necrosis factor-alpha improves postischemic recovery of hypertrophied hearts.

Stamm C, Friehs I, Cowan DB, Moran AM, Cao-Danh H, Duebener LF, del Nido PJ, McGowan FX Jr.

Circulation. 2001 Sep 18;104(12 Suppl 1):I350-5.

PMID:
11568081
[PubMed - indexed for MEDLINE]
Free Article
16.

Mechanistic relationship between membrane type-1 matrix metalloproteinase and the myocardial response to pressure overload.

Zile MR, Baicu CF, Stroud RE, Van Laer AO, Jones JA, Patel R, Mukherjee R, Spinale FG.

Circ Heart Fail. 2014 Mar 1;7(2):340-50. doi: 10.1161/CIRCHEARTFAILURE.113.000984. Epub 2014 Jan 6.

PMID:
24395927
[PubMed - indexed for MEDLINE]
17.

Loss of PTEN attenuates the development of pathological hypertrophy and heart failure in response to biomechanical stress.

Oudit GY, Kassiri Z, Zhou J, Liu QC, Liu PP, Backx PH, Dawood F, Crackower MA, Scholey JW, Penninger JM.

Cardiovasc Res. 2008 Jun 1;78(3):505-14. doi: 10.1093/cvr/cvn041. Epub 2008 Feb 15.

PMID:
18281373
[PubMed - indexed for MEDLINE]
Free Article
18.

Selective matrix metalloproteinase inhibition reduces left ventricular remodeling but does not inhibit angiogenesis after myocardial infarction.

Lindsey ML, Gannon J, Aikawa M, Schoen FJ, Rabkin E, Lopresti-Morrow L, Crawford J, Black S, Libby P, Mitchell PG, Lee RT.

Circulation. 2002 Feb 12;105(6):753-8.

PMID:
11839633
[PubMed - indexed for MEDLINE]
Free Article
19.

Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease.

Ahmed SH, Clark LL, Pennington WR, Webb CS, Bonnema DD, Leonardi AH, McClure CD, Spinale FG, Zile MR.

Circulation. 2006 May 2;113(17):2089-96. Epub 2006 Apr 24.

PMID:
16636176
[PubMed - indexed for MEDLINE]
Free Article
20.

Matrix metalloproteinase-19 inhibits growth of endothelial cells by generating angiostatin-like fragments from plasminogen.

Brauer R, Beck IM, Roderfeld M, Roeb E, Sedlacek R.

BMC Biochem. 2011 Jul 25;12:38. doi: 10.1186/1471-2091-12-38.

PMID:
21787393
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk